Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Obrien

Plastic Surgery Within the Head and Neck St Petersburg, FL Medical Doctor

NPI 1255445862 CMS profile 11373

7855 38Th Ave N, St Petersburg, FL 33710

Open in the dashboard

General payments

$3,998

47 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Obrien of St Petersburg, FL is reported in the CMS Open Payments database as having received $3,998 across 47 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Plastic Surgery Within the Head and Neck profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $296 7
2024 General $735 5
2023 General $1,270 18
2022 General $779 8
2021 General $139 3
2020 General $235 2
2019 General $544 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Obrien
  • Plastic Surgery Within the Head and Neck median
  • Middle half of Plastic Surgery Within the Head and Neck
  • National median

In program year 2025, general payments to John Obrien were reported at $296. Among 103 Plastic Surgery Within the Head and Neck profiles paid that year, the median was $300 and the middle half received between $115 and $580.

Show as a table
Year John Obrien Plastic Surgery Within the Head and Neck median Middle half National median
2019 $544 $270 $76–$780 $163
2020 $235 $172 $52–$421 $114
2021 $139 $227 $64–$753 $132
2022 $779 $338 $112–$800 $149
2023 $1,270 $303 $89–$723 $160
2024 $735 $289 $115–$714 $164
2025 $296 $300 $115–$580 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Integra LifeSciences Corporation $1,329 10 payments
  2. Merz North America, Inc. $1,056 8 payments
  3. Mentor Worldwide LLC $358 4 payments
  4. TELA Bio, Inc. $335 3 payments
  5. Sientra, Inc. $227 2 payments
  6. AbbVie, Inc. $194 6 payments
  7. Smith+Nephew, Inc. $178 1 payment
  8. Motiva USA, LLC $139 3 payments
  9. Galderma Laboratories, L.P. $47 3 payments
  10. Allergan Inc. $31 2 payments
  11. Other $104 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,249 45 payments
  2. Long term medical supply or device loan $749 2 payments
Products named General payments · program years 2019–2025
  1. DuraSorb Monofilament Mesh $803 5 payments
  2. INTEGRA DERMAL REGENERATION TEMPLATE $526 5 payments
  3. Integra Recon-Skin And Wound $418 4 payments
  4. Integra Recon-Skin And Wound $418 4 payments
  5. OMNIGRAFT $418 4 payments
  6. SURGIMEND $418 4 payments
  7. MENTOR MemoryGel Resterilizable Gel Sizer $358 4 payments
  8. Xeomin $340 4 payments
  9. ASCLERA $254 1 payment
  10. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $227 2 payments
  11. Other $1,327 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

94

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$712

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

21.3%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 20 $270
Scopolamine Generic 20 $241
Cephalexin Generic 37 $148
Triamcinolone Acetonide Generic 17 $53

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Records

47 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery Within the Head and Neck in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record